AMANDA EYMARD: Open Payments
NPI 1790162626 · HOUMA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$164,238 in 350 payments from 13 companies in 2025. Trend: 2023 $120,908 · 2024 $181,355 · 2025 $164,238
Speaker / faculty: $97,057Honoraria: $33,638Travel & lodging: $15,427Consulting: $11,278Food & beverage: $6,608Education: $231
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 73 | $38,095 |
| Neurocrine BioSciences, Inc. | 59 | $37,737 |
| Otsuka America Pharmaceutical, Inc. | 71 | $36,896 |
| Alkermes, Inc. | 72 | $28,064 |
| Teva Pharmaceuticals USA, Inc. | 38 | $19,381 |
| ABBVIE INC. | 15 | $3,495 |
| E.R. Squibb & Sons, L.L.C. | 10 | $183 |
| Janssen Scientific Affairs, LLC | 1 | $143 |
| Janssen Pharmaceuticals, Inc | 6 | $137 |
| Corium, LLC | 2 | $34 |
Products named: Auvelity, INGREZZA, REXULTI, UZEDY, ARISTADA, LYBALVI, VRAYLAR, COBENFY.
Industry payments across LA — which companies pay providers there.
